newsfilter
← Latest News
GlobeNewswire·

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose